Is Halozyme Back?
BMO Capital Markets gave Halozyme an upgrade today, pushing the company's price target up from $4 to an incredible $12, which has shares up 15%. In the following video, Motley Fool health care analyst David Williamson takes us through BMO's thought process for an upgrade and Halozyme's upcoming catalysts.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock-picking service: Supernova. Just click here now for instant access.
The article Is Halozyme Back? originally appeared on Fool.com.David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid.Max Macaluso has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.